A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes

Phase 1

Completed

• Conditions: Type 2 Diabetes Mellitus
• Interventions: Drug: Exenatide and placebo

• Registration Number: NCT00517283
• Lead Sponsor: AstraZeneca

Brief Summary

As exenatide slows the rate at which materials leave the stomach, it is likely to alter the rate of intestinal absorption of oral drugs when administered within a certain timeframe relative to exenatide. In addition, the residence time within the stomach of other medication may be prolonged and data from this study will help assess the change in residence time in the presence of therapeutic doses of exenatide. This study will also evaluate the relationship between blood levels of exenatide and parameters measuring rate of stomach emptying.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-01
• Primary Completion: 2005-06
• Study Completion: 2005-06
• Study First Submitted: 2007-08-14
• Study First Submitted QC: 2007-08-14
• Study First Posted: 2007-08-16
• Status Verified: 2015-01
• Last Update Submitted: 2015-02-20
• Last Update Posted: 2015-02-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 17

Inclusion Criteria

• Subjects with at least 1 year history of type 2 diabetes mellitus.
• Subjects controlled by oral antidiabetic agents or diet and exercise demonstrated by a screening HbA1c ≥7.0% and ≤10.0%.
• Between the body mass index (BMI) of 19 kg/m2 and 40 kg/m2, inclusive.

Read More

Exclusion Criteria

• Within 4 months of the initial dose of study drug, have received a drug that has not received regulatory approval for any indication.
• Persons who have previously completed or withdrawn from this study or any other study investigating exenatide.
• Subjects who are using drugs that significantly affect gastrointestinal motility (including acarbose, metoclopramide, and macrolide antibiotics).
• Subjects who intend to start new concomitant medication during the study, including over-the counter medication, apart from occasional intake of paracetamol or vitamin/mineral supplements. Anti-emetic medication may be permitted at the investigator's discretion, except those that affect gastrointestinal motility.
• Subjects who have used insulin for more than 4 weeks within 3 months prior to screening.
• Blood donation of more than 500 mL in the last 3 months of screening or any blood donation within the last month.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Sequence 2	Exenatide and placebo	Exenatide 10 mcg - Placebo - Exenatide 5 mcg
Sequence 3	Exenatide and placebo	Placebo - Exenatide 5 mcg - Exenatide 10 mcg
Sequence 1	Exenatide and placebo	Exenatide 5 mcg - Exentatide 10 mcg - Placebo

Primary Outcome Measures

Name	Time	Method
To detect the mean difference in half gastric emptying time for a solid meal between any treatment and placebo	up to 12 hours post meal consumption	A dose of exenatide or placebo is given before the morning meal. After eating the test meal, images will be recorded at approximately 5 minute intervals from ingestion of the test meal until 3 hours after the meal, then every 10 minutes until 6 hours after the meal. In cases where significant radioactivity is observed at 6 hours after the meal, additional scintigraphic images may be taken periodically at the discretion of the investigator, until counts approach low values for up to 12 hours after the meal.

Trial Locations

Locations (1)

Research Site; 🇬🇧 Nottingham, United Kingdom